Breast Cancer Virtual Journal Club | Lapatinib Plus Letrozole Effective as First-Line Therapy
for Metastatic HER2-Amplified, Endocrine-Responsive Breast Cancer
Expert perspectives with Stephen R. D. Johnston, MA, PhD, FRCP
|
This independent medical education activity features an expert interview focusing on important data from the recent oncology literature in the field of breast cancer.
Stephen R. D. Johnston, MA, PhD, FRCP, is interviewed regarding the published results of the EGF30008 trial of lapatinib plus letrozole in women with hormone receptor–positive, HER2-positive metastatic breast cancer, and how these results may affect clinical practice.
|
|
Target Audience | The information on this site is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before accessing the Webcast and slides. This site may contain information on products outside the approved indications where you practice.
|
|
|
Support | Supported by an educational grant
from GlaxoSmithKline.
|
|
|
|
Featured Experts |
 |
|
Speaker
Stephen R. D. Johnston, MA, PhD, FRCP
Royal Marsden Hospital
London, United Kingdom
|
| |
|
|
 |
|
Interviewer
Lee Lokey, MD
Senior Medical Director
prIME Oncology
Atlanta, Georgia, United States
|
|
Activity Date | This Webcast is available from 7 May 2010 to 7 May 2011.
|
|
